Neovacs SA ALNEV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €0.08
- Day Range
- €0.07–0.08
- 52-Week Range
- €0.06–316.00
- Bid/Ask
- €0.07 / €0.08
- Shares Outstanding
- 159,828.00
- Market Cap
- €3.22
- Volume/Avg
- 307,344 / 109,724
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Neovacs SA is a biotechnology company focused on the development of "Kinoids", therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 11
- Website
- http://www.neovacs.fr
Valuation
Metric | ALNEV |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.00 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ALNEV |
|---|---|
Quick Ratio | 0.56 |
Current Ratio | 0.61 |
Interest Coverage | — |
Quick Ratio
ALNEV
Profitability
Metric | ALNEV |
|---|---|
Return on Assets (Normalized) | −18.91% |
Return on Equity (Normalized) | −23.29% |
Return on Invested Capital (Normalized) | −28.20% |
Return on Assets
ALNEV
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|pqyq?<> | LOCK|?n^& | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|Hkn^&KM | LOCK|FNZ?Z | $99B | |||
| Moderna Inc MRNA | LOCK|&>&^>Fl | LOCK|X$b | $90B | |||
| argenx SE ADR ARGX | LOCK|FP?B>^ | LOCK|H<K | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|FfCy>Vz | LOCK|v@n | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|s%@!tb?# | LOCK|YqNVh | $31B | |||
| Incyte Corp INCY | LOCK|^fnfdt% | LOCK|>Mk | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|lJj?pGh | LOCK|ZhRfm | $22B | |||
| BioNTech SE ADR BNTX | LOCK|&v%SR! | LOCK|BH | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|gzd!lyB | LOCK|Zt | $16B |
United States